binding substances

Agglomerated cork (with or without a binding substance) and articles of agglomerated cork:

Agglomerated cork (being cork agglomerated with or without a binding substance) and articles of agglomerated cork

Agglomerated cork (being cork agglomerated with-or without a binding substance) and articles of agglomerated cork

Agglomerated cork (being cork agglomerated with or without a binding substance) and articles of agglomerated cork:

Particle board and similar board of wood or other ligneous materials, whether or not agglomerated with resins or other organic binding substances:

stabilisers include substances which enable the maintenance of a homogenous dispersion of two or more immiscible substances in a foodstuff, substances which stabilise, retain or intensify an existing colour of a foodstuff and substances which increase the binding capacity of the food, including the formation of cross-links between proteins enabling the binding of food pieces into re-constituted food;

In this respect, reports of plasma protein binding studies, hepatic metabolism and active substance interaction studies and studies using human bio-materials shall be provided.

Particle board and similar board (for example, oriented strand board and waferboard) of wood or other ligneous materials, whether or not agglomerated with resins or other organic binding substances

Reconstituted wood, being wood shavings, wood chips, sawdust, wood flour or other ligneous waste agglomerated with natural or artificial resins or other organic binding substances, in sheets, blocks or the like

Reconstituted wood, being wood shavings, wood chips, sawdust, wood flour or other ligneous waste agglomerated with natural or artificial resins or other organic binding substances, in sheets, blocks or the like:

Panels, boards, tiles, blocks and similar articles of vegetable fibre, of wood fibre, of straw, of wood shavings or of wood waste (including sawdust), agglomerated with cement, plaster or with other mineral binding substances

Other NSAIDs, diuretic and substances with high protein binding may compete for binding and lead to toxic effects.

Other NSAIDs, diuretics and substances with high protein binding may compete for binding and lead to toxic effects.

It stops a chemical in the body (substance P) from binding to the NK1 receptors.

The in vitro plasma protein binding is approximately 60 %, suggesting little risk of active substance interaction due to protein binding.

Concurrent use of other substances with a high degree of protein binding may compete with masitinib binding and thus cause adverse effects.

Other NSAIDs, diuretics, anticoagulants and substances with high plasma protein binding may compete for binding leading to potentially toxic effects.

The active substance in Bridion, sugammadex, is a ‘ selective relaxant binding agent’.

Concurrent use of other active substances that have a high degree of protein binding may compete with firocoxib for binding and thus lead to toxic effects.

Concurrent use of other active substances that have a high degree of protein binding may compete with robenacoxib for binding and thus lead to toxic effects.

Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances with high protein binding may compete for binding and thus lead to toxic effects.

Other NSAIDS, diuretics, anticoagulants, aminoglycoside antibiotics and substances with high protein binding may compete for binding and thus lead to toxic effects.

Interactions Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances with high protein binding may compete for binding and thus lead to toxic effects.

It prevents a peptide (“ Substance P”) from binding to the NK1 receptors, which is involved in causing vomiting.

Prasugrel stops the platelets aggregating by blocking a substance called ADP from binding to a receptor on their surface.

TMZ demonstrates low protein binding (10 % to 20 %), and thus it is not expected to interact with highly protein-bound substances.

Clopidogrel stops the platelets aggregating by blocking a substance called ADP from binding to a special receptor on their surface.

the waste contains no other hazardous substances than bound asbestos, including fibres bound by a binding agent or packed in plastic,

Plasma protein binding is low at therapeutic concentrations and ibandronic acid is therefore unlikely to displace other active substances.

Clopidogrel, the active substance in Plavix, stops the platelets aggregating by blocking a substance, ADP, from binding to a special receptor on their surface. This stops the platelets

Concurrent use of other substances that have a high degree of protein binding (e. g. furosemide, ketoconazole, or non-steroidal anti-inflammatory drugs (NSAIDs)) may compete with cefovecin binding and thus may cause adverse effects.

Maropitant is a neurokinin 1 (NK1) receptor antagonist, which acts by inhibiting the binding of substance P, a neuropeptide of the tachykinin family.

stabilisers include substances which enable the maintenance of a homogenous dispersion of two or more immiscible substances in a foodstuff, substances which stabilise, retain or intensify an existing colour of a foodstuff and substances which increase the binding capacity of the food, including the formation of cross-links between proteins enabling the binding of food pieces into re-constituted food;"

The plasma protein binding of lansoprazole is about 95 %, but this has not been found to have a significant effect on other protein bound active substances.

Clopidogrel, the active substance in Iscover, stops the platelets aggregating by blocking a substance, ADP, from binding to a special receptor on their surface. This stops the platelets becoming ‘ sticky’.

The likelihood of metabolic interactions is low due to limited metabolism and plasma protein binding and almost complete renal elimination of unchanged substance.

By inhibiting the binding of substance P within the emetic centre, maropitant is effective against neural and humoral (central and peripheral) causes of vomiting.

At present no legally binding rules exist regulating the transmission of seized controlled narcotic substance samples between the authorities of the Member States.

The second is a glycosaminoglycan binding domain responsible for the interaction with heparin and related substances, which accelerates the inhibition of thrombin.

The likelihood of metabolic substance interactions with lamivudine is low due to the small (5-10 %) extent of hepatic metabolism and the low plasma protein binding.

In this respect, reports of plasma protein binding study, hepatic metabolism and active substance interaction studies and studies using other human bio-materials shall be provided.

Maropitant is a potent and selective neurokinin (NK-1) receptor antagonist, which acts by inhibiting the binding of substance P, a neuropeptide of the tachykinin family, in the CNS.

The substance binds with high affinity to the ATP-binding site in such a manner that it is a potent inhibitor of wild-type Bcr-Abl and maintains activity against 32/ 33 imatinib-resistant mutant forms of Bcr-Abl.

Because gadofosveset is bound to albumin, an interaction with other plasma protein bound active substances (e. g., ibuprofen and warfarin) is generally possible, i. e., a competition for the protein binding site can occur.

The active substance in IPLEX, mecasermin rinfabate, is a binary protein made up of two proteins that are normally produced by the body: insulin-like growth factor I (IGF-I) and insulin-like growth factor binding protein 3 (IGFBP-3).

Other non steroidal anti-inflammatory drugs (NSAID) must not be used simultaneously with the product and within 24 hours after the last dose of Dolovet because the substances may compete in binding with proteins thus leading to toxic effects.

Other non steroidal anti-inflammatory drugs (NSAID) must not be used simultaneously with the product and within 24 hours after the last dose of Dolovet, because the substances may compete in binding with proteins thus leading to toxic effects.

In binding to these neuronal NCCs ziconotide inhibits the voltage sensitive calcium current into primary nociceptive afferents terminating in the superficial layers of the dorsal horn of the spinal cord. In turn, this inhibits their release of neurotransmitters (including Substance P) and therefore, the spinal signalling of pain.

Overall evaluation with regard to all toxicological data, and other information concerning the active substance Residues in or on treated products, food and feed Identification of breakdown and reaction products and of metabolites in treated plants or products Behaviour of residue of the active substance and its metabolites from the time of application until harvest or outloading of stored products - uptake and distribution in, and where relevant on, plants, kinetics of disappearance, binding to plant constituents, etc.